A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer

Abstract

Rosa Greasley,1 Mohammad Khabazhaitajer,1 Derek J Rosario2 1The Department of Oncology, The University of Sheffield, Sheffield, UK; 2The Department of Urology, Sheffield Teaching Hospitals, The Royal Hallamshire Hospital, Sheffield, UK Abstract: Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of cancer deaths among men in the western world. In the evolution of second generation anti-androgens, enzalutamide, a novel androgen-receptor signaling inhibitor, has emerged targeting multiple steps within the androgenic stimulation pathway. This review discusses what is currently known of the mechanisms surrounding castration resistant prostate cancer development and the current human clinical trials to determine whether enzalutamide presents a new hope for men with advanced prostate cancer. The issues of therapy resistance, withdrawal effects and cross-resistance are briefly touched upon. Keywords: enzalutamide, androgen receptor, metastatic castrate resistant prostate cancer, MDV3100, anti-androgen